{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:29:45Z","timestamp":1784071785647,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100807","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T19:58:48Z","timestamp":1612641528000},"page":"100807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders"],"prefix":"10.1016","volume":"49","author":[{"given":"Akihiro","family":"Ohmoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100807_bb0005","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2021.100807_bb0010","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. 2017 WHO classification of tumours of haematopoietic and lymphoid tissues, IARC Publication, 4th ed., 443."},{"key":"10.1016\/j.blre.2021.100807_bb0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma","volume":"7335","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2021.100807_bb0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4132\/jptm.2017.03.15","article-title":"Epstein-Barr virus-associated lymphoproliferative disorders: Review and update on 2016 WHO classification","volume":"51","author":"Kim","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.blre.2021.100807_bb0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11899-007-0034-y","article-title":"Epstein-Barr virus-related lymphoproliferative disorders","volume":"2","author":"Wagner-Johnston","year":"2007","journal-title":"Hematol Malig Rep"},{"key":"10.1016\/j.blre.2021.100807_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/pathogens7030059","article-title":"Contribution of Epstein\u2013Barr virus latent proteins to the pathogenesis of classical Hodgkin lymphoma","volume":"7","author":"Vrzalikova","year":"2018","journal-title":"Pathogens"},{"key":"10.1016\/j.blre.2021.100807_bb0035","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2019004126","article-title":"Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy","volume":"135","author":"Dalton","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz171","article-title":"Determination of epstein-barr virus\u2013infected lymphocyte cell types in peripheral blood mononuclear cells as a valuable diagnostic tool in hematological diseases","volume":"6","author":"Zhang","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.blre.2021.100807_bb0045","series-title":"B-cell lymphomas","article-title":"Clinical practice guidelines in oncology","author":"NCCN","year":"2020"},{"key":"10.1016\/j.blre.2021.100807_bb0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2010.039214","article-title":"Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: A prospective analysis of 8 cases","volume":"96","author":"Trappe","year":"2011","journal-title":"haematologica"},{"key":"10.1016\/j.blre.2021.100807_bb0055","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2021.100807_bb0060","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/cncr.31339","article-title":"Impact of the posttransplant lymphoproliferative disorder subtype on survival","volume":"124","author":"Koff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100807_bb0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/gcc.20287","article-title":"Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities","volume":"45","author":"Djokic","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2021.100807_bb0070","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fonc.2020.00506","article-title":"Biological difference between Epstein\u2013Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact","volume":"10","author":"Ferla","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0075","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2012-04-421412","article-title":"How I treat HHV8\/KSHV-related diseases in posttransplant patients","volume":"120","author":"Riva","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0080","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/TP.0000000000002146","article-title":"The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: A single-center experience","volume":"102","author":"Peters","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2021.100807_bb0085","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bjh.14633","article-title":"Mutational landscape of B-cell post-transplant lymphoproliferative disorders","volume":"178","author":"Menter","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100807_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13145","article-title":"Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, a CIBMTR study","volume":"21","author":"Naik","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.blre.2021.100807_bb0095","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2021.100807_bb0100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3390\/cancers12020328","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: Pathogenesis, risk factors and clinical outcomes","volume":"12","author":"Fujimoto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2021.100807_bb0105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbmt.2018.02.026","article-title":"Epstein-Barr virus-related post-transplantation lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Liu","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100807_bb0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European conference on infections in leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100807_bb0115","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0120","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ajh.25116","article-title":"The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013","volume":"93","author":"Tsai","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100807_bb0125","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2021.100807_bb0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/TP.0000000000000255","article-title":"Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation","volume":"99","author":"Fukushima","year":"2015","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.blre.2021.100807_bb0135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2967\/jnumed.119.239624","article-title":"18F-FDG PET\/CT in the diagnostic and treatment evaluation of pediatric post-transplant lymphoproliferative disorders","volume":"61","author":"Montes de Jesus","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.blre.2021.100807_bb0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/10428194.2013.813501","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diagnosis of post-transplant lymphoproliferative disorder","volume":"55","author":"Panagiotidis","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100807_bb0145","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.2012.074500","article-title":"The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder","volume":"98","author":"Dierickx","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100807_bb0150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2019.00062","article-title":"EBV viral loads in diagnosis, monitoring, and response assessment","volume":"9","author":"Kimura","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720910964","article-title":"Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Liu","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2021.100807_bb0160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/CMR.00006-09","article-title":"Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder","volume":"23","author":"Gulley","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.blre.2021.100807_bb0165","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2015-09-672030","article-title":"The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases","volume":"127","author":"Kanakry","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0170","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/JCM.39.4.1211-1216.2001","article-title":"Toward standardization of Epstein-Barr virus DNA load monitoring: Unfractionated whole blood as preferred clinical specimen","volume":"39","author":"Stevens","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.blre.2021.100807_bb0175","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/rmv.582","article-title":"Measuring Epstein-Barr virus (EBV) load: The significance and application for each EBV-associated disease","volume":"18","author":"Kimura","year":"2008","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.blre.2021.100807_bb0180","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.blre.2021.100807_bb0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.19028","article-title":"Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients","volume":"59","author":"Saito","year":"2019","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.blre.2021.100807_bb0190","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0195","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: A nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.blre.2021.100807_bb0200","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100807_bb0205","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.blre.2021.100807_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0215","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: Clinicopathologic features and prognostic factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.blre.2021.100807_bb0220","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/cas.13249","article-title":"Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types","volume":"108","author":"Gion","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.blre.2021.100807_bb0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1349-7006.2010.01517.x","article-title":"Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate","volume":"101","author":"Niitsu","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.blre.2021.100807_bb0230","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.3109\/10428194.2015.1022769","article-title":"Methotrexate-associated lymphoproliferative disorders: Management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal","volume":"56","author":"Inui","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100807_bb0235","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2018.00621","article-title":"Restoration of decreased T helper 1 and CD8+ T cell subsets is associated with regression of lymphoproliferative disorders developed during methotrexate treatment","volume":"9","author":"Saito","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100807_bb0240","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00277-018-3327-4","article-title":"The prognostic value of positron emission tomography\/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders","volume":"97","author":"Takanashi","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100807_bb0245","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1186\/s12885-016-2672-8","article-title":"The usefulness of 18F-FDG PET\/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)","volume":"16","author":"Watanabe","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2021.100807_bb0250","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/modpathol.2009.131","article-title":"Immunomodulator agent-related lymphoproliferative disorders","volume":"22","author":"Hasserjian","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2021.100807_bb0255","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/s41379-018-0054-2","article-title":"Other immunomodulatory agent-related lymphoproliferative diseases: A single-center series of 72 biopsy-confirmed cases","volume":"31","author":"Marcelis","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.blre.2021.100807_bb0260","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/cimm.1993.1193","article-title":"An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites","volume":"150","author":"Kozarsky","year":"1993","journal-title":"Cell Immunol"},{"key":"10.1016\/j.blre.2021.100807_bb0265","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V89.4.1308","article-title":"CD2 regulates the positive selection and function of antigen-specific CD4\u2212CD8+ Tcells","volume":"89","author":"Teh","year":"1997","journal-title":"Blood"},{"issue":"6 Suppl 5","key":"10.1016\/j.blre.2021.100807_bb0270","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2007.11.003","article-title":"Pharmacology and mechanism of action of forodesine, a T-cell targeted agent","volume":"34","author":"Gandhi","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0275","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/1078-0432.CCR-08-1254","article-title":"EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies","volume":"15","author":"O\u2019Mahony","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2021.100807_bb0280","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-018-3418-2","article-title":"Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma","volume":"98","author":"Maruyama","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100807_bb0285","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","article-title":"Final results of a multicenter phase II study of the purine nucleoside phos phorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and S\u00e9zary syndrome)","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0290","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.blre.2021.100807_bb0295","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/TP.0b013e3181dd6c0a","article-title":"A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation","volume":"89","author":"Cesaro","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.blre.2021.100807_bb0300","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.transproceed.2015.03.017","article-title":"Post-transplant lymphoproliferative disorder: A single-center experience","volume":"47","author":"Ferreira","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.blre.2021.100807_bb0305","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.blre.2021.100807_bb0310","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonz\u00e1lez-Barca","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100807_bb0315","article-title":"Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100807_bb0320","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0325","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.16304","article-title":"Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder","volume":"189","author":"Jain","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100807_bb0330","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/bjh.16371","article-title":"Real-world outcomes of post-transplant lymphoproliferative disorder treated with risk-stratified sequential therapy","volume":"189","author":"DeStefano","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100807_bb0335","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): A Children\u2019s oncology group report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.blre.2021.100807_bb0340","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1172\/JCI90599","article-title":"Immunotherapy for transplantation-associated viral infections","volume":"127","author":"Roddie","year":"2017","journal-title":"Clin Investig"},{"key":"10.1016\/j.blre.2021.100807_bb0345","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0350","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0355","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3324\/haematol.2018.207548","article-title":"Long-term follow up after third-party viral-specific cytotoxic lymphocytes for immunosuppression- and Epstein-Barr virus-associated lymphoproliferative disease","volume":"104","author":"Kazi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2021.100807_bb0360","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0365","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0370","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100807_bb0375","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10428194.2018.1480767","article-title":"Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation","volume":"60","author":"Kinch","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100807_bb0380","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2021.100807_bb0385","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100807_bb0390","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","article-title":"Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation","volume":"131","author":"Soiffer","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100807_bb0395","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2019-127390","article-title":"A Phase I\/II trial of brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients with immunosuppression-associated CD30+ and\/or EBV+ lymphomas","volume":"134","author":"Pearse","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0400","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2021.100807_bb0405","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2014.966242","article-title":"Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders","volume":"56","author":"Vase","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100807_bb0410","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0284186X.2020.1731924","article-title":"CD30 expression and survival in posttransplant lymphoproliferative disorders","volume":"59","author":"Kinch","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.blre.2021.100807_bb0415","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100807_bb0420","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH questionnaire-based cross-sectional survey","volume":"21","author":"San-Juan","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.blre.2021.100807_bb0425","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:51Z","timestamp":1759436691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":85,"alternative-id":["S0268960X21000138"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100807","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100807"}}